FDA Initiates Class III Recall for Annora Pharma's Pitavastatin Calcium Due to Foreign Tablet Contamination
Annora Pharma Private Limited faces an FDA Class III recall for 770 bottles of Pitavastatin Calcium 2mg tablets, distributed by NorthStar RxLLC, due to foreign 1mg tablets found in 2mg bottles. This event highlights critical quality control deficiencies at Annora Pharma's Hyderabad facility, necessitating immediate supply chain risk assessment for procurement and regulatory teams.
FDA Identifies Critical Packaging Anomaly in Annora Pharma's Pitavastatin Calcium Supply
The U.S. Food and Drug Administration (FDA) has initiated a Class III recall, D-0391-2026, for Pitavastatin Tablets, 2 mg, manufactured by Annora Pharma Private Limited in India. This voluntary, firm-initiated recall, which began on February 3, 2026, stems from the discovery of foreign tablets within product bottles. Specifically, one 1mg Pitavastatin tablet was found in a bottle designated for 2mg Pitavastatin tablets. This critical quality control failure affects Lot #: A252487, with an expiration date of May 31, 2027, impacting 770 bottles distributed by NorthStar Rx LLC in Memphis, TN. For procurement directors, this incident signals an immediate need to quarantine and verify inventories of Pitavastatin Calcium from Annora Pharma, particularly Lot A252487. The presence of incorrect strengths within a single container poses a direct risk to patient safety through potential under-dosing or over-dosing, which can compromise treatment efficacy for conditions managed by Pitavastatin Calcium. Regulatory affairs heads must recognize this as a significant deviation from Good Manufacturing Practices (GMP) that demands rigorous investigation and corrective action from Annora Pharma, impacting the reliability of their supply chain. This event underscores the imperative for robust quality assurance protocols throughout the packaging process to prevent cross-contamination of different strengths or products.
Annora Pharma's Hyderabad Facility Under Scrutiny for Pitavastatin Calcium Quality Control
Annora Pharma Private Limited, located at Sy. No.261, Plot No. 13 And 14, Annaram Village, Gummadidal Mandal, Jinnaram Mandal, Sangareddy District, Medak, Hyderabad, India, is the manufacturing site implicated in this Class III recall. The affected product, Pitavastatin Calcium, is a human prescription drug administered orally, identified by application number ANDA205977 and NDCs 72603-479-01 and 72603-480-01 for the 2mg strength. This facility's role as a manufacturer for NorthStar RxLLC, which distributes the product in Tennessee, highlights its integration into the U.S. pharmaceutical supply chain. For supply chain VPs, this recall directly impacts the availability and integrity of Pitavastatin Calcium sourced from this specific Indian facility. The incident raises questions about the facility's packaging lines, segregation procedures, and overall quality management system, particularly concerning product differentiation and prevention of mix-ups. The recall of 770 bottles, while not a massive quantity, represents a complete batch failure for Lot A252487, indicating a systemic issue rather than an isolated incident. Business development executives should note that such quality lapses from a key manufacturing site can erode market confidence and prompt a re-evaluation of supplier relationships, potentially opening opportunities for alternative manufacturers of Pitavastatin Calcium.
Supply Chain Exposure and Commercial Implications for Pitavastatin Calcium
The recall of Pitavastatin Tablets, 2 mg, manufactured by Annora Pharma Private Limited and distributed by NorthStar RxLLC, directly impacts the U.S. market, specifically Tennessee, where the product was distributed. While the immediate distribution pattern is limited to TN, the implications for NorthStar RxLLC and its downstream partners are broader. Procurement directors must assess their inventory of Pitavastatin Calcium, particularly any stock originating from Annora Pharma, regardless of the distribution state, as the manufacturing defect points to a systemic issue at the source. The brand name for this generic is Pitavastatin Calcium, a widely used statin for hyperlipidemia, meaning any disruption could affect patient access. The recall of 770 bottles of Lot A252487, while not representing a market-wide shortage, necessitates immediate action to ensure no mislabeled product reaches patients. Regulatory affairs heads should advise their organizations on the potential for increased scrutiny on all products sourced from Annora Pharma's Hyderabad facility, not just Pitavastatin Calcium. This event could trigger enhanced import controls or require additional quality attestations for future shipments. Business development executives should monitor the market response, as competitors offering Pitavastatin Calcium may gain an advantage if Annora Pharma's supply chain reliability is perceived to be compromised, potentially leading to shifts in market share.
Navigating Supply Chain Risk: Absence of Readily Available Pitavastatin Calcium Alternatives
For procurement directors and supply chain VPs, the immediate challenge posed by Annora Pharma's Pitavastatin Calcium recall is the lack of readily identified alternative suppliers within current ChemLifeIntel intelligence. This absence means that organizations relying on Annora Pharma for this crucial molecule must proactively initiate their own due diligence to identify and qualify new sources. The process of qualifying a new pharmaceutical supplier, especially for an active pharmaceutical ingredient (API) or finished dosage form like Pitavastatin Calcium, can be extensive, often spanning 12 to 24 months due to rigorous regulatory requirements, audit processes, and stability testing. This timeline underscores the urgency for immediate action. Companies should consider geographical diversification in their sourcing strategies to mitigate future single-point-of-failure risks. Without pre-qualified alternatives, any further regulatory action against Annora Pharma or its Hyderabad facility could lead to significant supply disruptions, impacting product availability and market commitments. Business development executives should leverage this intelligence to identify potential gaps in competitor supply chains and explore opportunities for strategic partnerships or in-house manufacturing capabilities for Pitavastatin Calcium.
Annora Pharma's Regulatory Posture: A Critical First Recorded FDA Action
This Class III recall marks the first recorded significant regulatory action by the FDA against Annora Pharma Private Limited within the scope of ChemLifeIntel's current knowledge graph. While no prior Warning Letters, 483s, or Import Alerts are immediately evident for Annora Pharma's Hyderabad facility, this incident establishes a critical regulatory precedent. For regulatory affairs heads, this means that Annora Pharma is now firmly on the FDA's radar, and future inspections or product submissions will likely face heightened scrutiny. The absence of a historical pattern of non-compliance does not diminish the severity of this specific quality control failure; rather, it indicates that this event will be a foundational element in their developing regulatory profile. Supply chain VPs should anticipate that any subsequent issues, even minor ones, could lead to an accelerated escalation of regulatory enforcement, including potential Import Alerts or more severe classifications. This situation demands that Annora Pharma implement comprehensive corrective and preventive actions (CAPA) that are not only effective but also thoroughly documented and verifiable by the FDA. The initial firm notification via letter and voluntary recall status indicate a degree of cooperation, but the underlying root cause of the foreign tablet presence must be definitively addressed to restore confidence.
Remediation Timeline and Future Outlook for Annora Pharma's U.S. Market Access
The recall of Pitavastatin Calcium is currently ongoing, with the initial firm notification on February 3, 2026, and the FDA's center classification on March 16, 2026. Annora Pharma Private Limited is now obligated to conduct a thorough root cause analysis and implement robust corrective and preventive actions (CAPA) to address the foreign tablet contamination. For regulatory affairs heads, this means monitoring Annora Pharma's response, which typically involves submitting a detailed action plan to the FDA outlining how they will prevent recurrence. The FDA will evaluate the adequacy and effectiveness of these CAPA measures. Failure to implement satisfactory remediation could lead to further regulatory enforcement, including potential Warning Letters, increased inspection frequency, or even an Import Alert, which would severely restrict or halt all future shipments of Annora Pharma products to the U.S. Procurement directors must factor this potential for escalation into their risk assessments for all products sourced from Annora Pharma. While a Class III recall is less severe than Class I or II, it still signifies a breakdown in quality systems. Business development executives should prepare for potential market volatility and competitive shifts if Annora Pharma's ability to supply the U.S. market with Pitavastatin Calcium or other products is compromised in the long term, creating opportunities for alternative suppliers to capture market share.